Abstract
The purpose of this study was to evaluate the protective effect of a new endotoxin analogue, monophosphoryl lipid A (MLA) in a rabbit model of myocardial ischemia/reperfusion and to show if this protection was mediated via synthesis of 70 kDa heat shock protein (HSP 70). Three groups of New Zealand White rabbits underwent 30 min coronary occlusion, followed by 4 hours reperfusion. First group of rabbits (n = 6) were treated with 0.35 ml vehicle (40 % propylene glycol, 10% ethanol in water). The second and third group of rabbits (n = 6–8) were treated with MLA (35 μg/kg, i.v.) 12 and 24 hours prior to ischemia and reperfusion. MLA treatment either 12 or 24 h prior to ischemia/reperfusion demonstrated significantly reduced infarct size (12.5 ± 1.7 and 14.7 ± 2.1 % for 12 and 24 h) when compared with vehicle control (40.4 ± 8.6%, mean ± S.E.M, p < 0.05). No significant differences in the infarct size was observed between the 12 and 24 h MLA treated groups. The area at risk was not significantly different between the three groups. Baseline values of heart rate, systolic and diastolic blood pressure were not significantly different between the control and MLA treated groups. However, the systolic as well as diastolic blood pressure during reperfusion were significantly lower in rabbits treated with MLA. Western blot analysis of the protein extracts of the hearts (n = 2/group) demonstrated no increase in the expression of the inducible form of HSP 70 following treatment with MLA. We conclude that MLA has significant anti-infarct effect in rabbit which is not mediated by the cardioprotective protein HSP 70. The anti-infarct effect of this drug is superior to the reported protective effects of delayed ischemic or heat stress preconditioning. We hypothesize that the pharmacologic preconditioning afforded by MLA is accomplished via a unique pathway that bypasses the usual intracellular signaling pathways which lead to the myocardial protection with the expression of heat shock proteins.
Similar content being viewed by others
References
Kukreja RC, Yoshida K, Shipley JB, Deloresco M, Qian Y-Z, Maaieh M, Elliott GT: Pharmacologic ‘preconditioning’ with monophosphoryl lipid A in the rabbit heart is not mediated by the synthesis of a 70-kDa heat shock protein. J Mol Cell Cardiol 27: A164, 1995 (Abstract)
Morrison DC, Ryan JL: Bacterial endotoxins and host immune responses. Adv Immunol 28: 293–300, 1979
Nowotny A, Butler RC: Studies on the endotoxin induced tumor resistance. Adv Exp Med Biol 121: 455–469, 1980
Landy M, Pillemer L: Increased resistance to infection and accompanying alterations in properidin leves following administration of bacterial lipopolysaccharides. J Exp Med 104: 383–409, 1956
Brown JM, Grosso MA, Tarada GJ, Whitman GJ, Banerjee A, White CW, Harken AH, Repine JE: Endotoxin pretreatment increases endogenous myocardial catalase activity and decreases ischemia-reperfusion injury of isolated rat heart. Proc Natl Acad Sci USA 86: 2516–2520, 1989
Galanos C, Luderltz O, Rletschel ET, Westphal O: Newer aspects of the chemistry and biology of bacterial lipopolysaccharides, with special reference to their lipid A component, Biochemistry of Lipids II. T.W. Goodwin (ed.). 1977, pp 239–335
Ribi E: Beneficial modification of the endotoxin molecule. J Biol Resp Modif 3: 1–9, 1984
Qureshi N, Takayama K, Ribi E: Purification and structural determination of nontoxin lipid A obtained from lipopolysaccharide of salmonella tuphimurium. J Biol Chem 257: 11808–11815, 1982
Takayama K, Qureshi N, Ribi E, Cantrell JL, Amano K: Use of endotoxin in cancer immunotherapy and characterization of nontoxic but active lipid A components. ACS Symp 231: 219–233, 1983
Takayama K, Qureshi N, Raetz CRH, Ribi E, Peterson J, Cantrell JL, Pearson FC, Wiggins J, Johnson AG: Influence of fine structure of lipid A on limulus amebocyte lysate clotting and toxic activities. Infect Immun 45: 350–355, 1984
Nelson DW, Brown JM, Banerjee A, Bensard DD, Rogers KB: Pretreatment with a nontoxic derivative of endotoxin induces functional protection against cardiac ischemia/reperfusion injury. Surgery 110: 365–369, 1991
Yao Z, Auchampach JA, Pieper GM, Gross GJ: Cardioprotective effects of monophosphoryl lipid A, a novel endotoxin analogue, in the dog. Cardiovasc Res 27: 832–838, 1993
Yao Z, Rasmussen JL, Hirt JL, Mei DA, Pieper GM, Gross GJ: Effects of monophosphoryl lipid A on myocardial ischemia/reperfusion injury in dogs. J Cardiovasc Pharmacol 22: 653–663, 1993
Howard G, Geoghegan TE: Altered cardiac tissue gene expression during acute hypoxic exposure. Mol Cell Biol 69: 155–160, 1986
Low I, Friedrich T, Schoeppe W: Synthesis of heat shock proteins in cultured fetal mouse myocardial cells. Experimental Cell Research 180: 451–459, 1989
Delcayre C, Samuel JL, Marrothe F, Mescadier JJ, Rappaport L: Synthesis of stress proteins in rat cardiac myocytes 2–4 days after imposition of hemodynamic overload. J Clin Inv 82: 460–468, 1988
Kukreja RC, Kontos MC, Loesser KE, Batra SK, Qian Y-Z, Gbur C. Jr. Naseem SA, Jesse RL, Hess ML: Oxidant stress increases heat shock protein 70 mRNA in isolated perfused rat heart. Am J Physiol 267: H2213-H2219, 1994
Gutherie LA, McPhail LC, Henson PM, Johnston RB: Priming of neutrophils for enhanced release of oxygen metabolites by bacterial lipopolysaccharides. J Exp Med 160: 1656–1671, 1984
Laemmli U: Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature[Lond] 227: 680–685, 1970
Marber MS, Latchman DS, Walker JM, Yellon DM: Cardiac stress protein elevation 24 h after brief ischemia or heat stress is associated with resistance to myocardial infarction. Circulation 88: 1264–1272, 1993
Marber MS, Mestril R, Chi SH, Sayen MR, Yellon DM: A heat shock protein 70 transgene results in myocardial protection. J Clin Invest 95: 1446–1556, 1995
Plumier JC, Ross BM, Currie RW, Angelidis CE, Kazlaris H, Kollias G, Pagoulatos GN: Transgenic mice expressing human heat shock protein 70 have improved post-ischemic myocardial recovery. J Clin Invest 95: 1854–1860, 1995
Lavoie JN, Lambert H, Hickey E, Weber LA, Landry J: Modulation of cellular thermotolerance and actin filament stability accompanies phophorylation-induced changes in the oligomeric structure of heat shock protein 27. Mol Cell Biol 15: 505–516, 1995
Kukreja RC, Hess ML: Free Radicals, Cardiovascular Dysfunction and Protection Strategies. Austin, TX., R.G. Landes Company, 1994
Kukreja RC, Hess ML: The oxygen free radical system: from equations through membrane protein-interactions to cardiovascular injury and protection. Cardiovasc Res 26: 641–655, 1992
Currie RW, Ross BM, David TA: Induction of the heat shock response in rats modulate heart rat, creatine kinase and protein synthesis after subsequent hyperthermic treatment. Cardiovasc Res 14: 87–93, 1990
Murry CE, Jennings RB, Reimer KA: Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. Circulation 74: 1124–1136, 1986
Maulik N, Watanabe M, Engelman DT, Engelman M, Das DK: Oxidative stress adaptation improves postischemic ventricular recovery. Mol Cell Biochem 144: 67–74, 1995
Zingarelli B, Halushka PV, Caputi AP, Cook JA: Increased nitric oxide synthase during the development of endotoxin tolerance. Shock 3: 102–108, 1995
Mehta JL, Nichols WW, Donnelly WM, Lawson DL, Saldeen TGP: Impaired canine responses to acetylcholine and bradykinin after occlusion-reperfusion. Circ Res 64: 43–54, 1993
Ku D: Coronary vascular reactivity after acute myocardial ischemia. Science 218: 576–578, 1982
Armstrong PW, Walker DC, Burton JR, Parker JO: Vasodilator therapy in acute myocardial infarction: A comparison of sodium nitroprusside and nitroglycerin. Circulation 52: 1118–1122, 1975
Bussman WD, Passek D, Seidel W, Kaltenbach M: Reduction of CK and CK-MB indexes of infarct size by intravenous nitroglycerin. Circulation 63: 615–622, 1981
Flaherty JT, Becker LC, Bulkly BH, Weiss JL, Gerstenblith G, Kallman M, Silverman KJ, Wei JY, Pitt B, Weisfeldt ML: A randomized prospective trial of intravenous nitroglycerin in patients with acute myocardial infarction. Circulation 68: 576–588, 1993
Johnson III, G., Tsao PS, Lefer AM: Cardioprotective effects of authentic nitric oxide in myocardial ischemia with reperfusion. Critical Care Medicine 19: 244–252, 1991
Johnson III G, Tsao PS, Mulloy D, Lefer AM: Cardioprotective effects of acidified sodium nitrite in myocardial ischemia with reperfusion. J Pharmacol Exp Therap 252: 35–41, 1990
Perlmutter DH, Dinarello CA, Punsal PI, Colten HR: Cachectin/tumor necrosis factor regulates hepatic acute phase gene expression. J Clin Inv 78: 1349–1354, 1986
Dinarello CA: Interleukin I and the pathogenesis of the acute phase response. N Engl J Med 311: 1413–1418, 1984
Eddy LJ, Goeddel DV, Wong GHW: Tumor necrosis factor a pretreatment is protective in a rat model of myocardial ischemiareperfusion injury. Biochem Biophys Res Commun 184: 1056–1059, 1992
Brown JM, White CW, Terada LS, Grosso MA, Shanley PF, Mulvin DW, Banerjee A, Whitman GJR, Harken AH, Repine JE: Interleukin 1 pretreatment decreases ischemia/reperfusion injury. Proc Natl Acad Sci USA 87: 5026–5030, 1990
Wong GH, Goeddel DV. Induction of manganous superoxide dismutase by tumor necrosis factor: possible protective mechanism. Science 242: 941–944, 1988
Author information
Authors and Affiliations
Additional information
A preliminary form of this paper was presented at the XV World Congress of the International Society for Heart Research held in Prague, Czech Republic [17]. This work was supported in part by grants HL 46763 and 51045 from National Institutes of Health and a grant from RIBI ImmunoChem Research, Hamilton, Montana. JBS was supported from a training grant HL 07537 from National Institutes of Health.
Rights and permissions
About this article
Cite this article
Yoshida, Ki., Maaieh, M.M., Shipley, J.B. et al. Monophosphoryl lipid A induces pharmacologic ‘preconditioning’ in rabbit hearts without concomitant expression of 70-kDa heat shock protein. Mol Cell Biochem 156, 1–8 (1996). https://doi.org/10.1007/BF00239312
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00239312